SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment

NCT06010953 | Completed Phase 1

• 1 other identifier: SS-109-I02
• Study Type: interventional
• Target: 24
• Locations: 1 country
• Sites: 9

Brief Summary

This is an open-label, multicenter Phase 1Ib/2II clinical trial of SS109 in adult hemophilia patients (≥ 18 years) with FVIII or FIX inhibitors to evaluate the PK/PD profile of SS109 and NovoSeven® after a single dose in adult hemophilia patients with FVIII or FIX inhibitors, to assess the preliminary efficacy and PK profile of SS109 during on-demand treatment, and to observe the safety and immunogenicity of SS109 throughout the study. The trial consists of three periods: screening period, PK study period, and on-demand treatment period. In the PK study period, subjects are divided into 2 cohorts (90 μg/kg and 270 μg/kg), which are sequentially conducted. Cohort 1 (90 μg/kg) enrollment is performed firstly, and Cohort 2 (270 μg/kg) enrollment is performed after Cohort 1 enrollment is completed. Subjects enter the PK study period as non-randomized. All screened eligible subjects will receive a single dose of comparator NovoSeven® in the absence of significant active hemorrhage, followed by PK/PD sample collection; then receive a single dose of the same dose of investigational drug SS109, followed by PK/PD sample collection. Specific times for PK/PD sample collection are listed in the schedule for biological sample collection. After completion of the PK study period, subjects will enter a 90-day on-demand treatment period and will be randomized into 3 groups (Group 1: 90 µg/kg, Group 2: 180 µg/kg, and Group 3: 270 µg/kg) at a ratio of 1:1:1. During on-demand treatment, subjects are treated on-demand with SS109 at the time of a new hemorrhage event and their efficacy is observed. The investigator will judge the severity of subject's hemorrhage according to the type, location, clinical symptoms and signs of the subject's hemorrhage. Appropriate hemostatic treatment regimens and whether or not to perform the first SS109 on-demand treatment for the hemorrhage event at home may be developed by the investigator based on the subject's on-demand treatment group, according to the severity of hemorrhage and the recommended dosing frequency of SS109 (see Dosage/Regimen), and the dosing interval may be adjusted in conjunction with the subject's response to treatment. If the subject's last hemostatic treatment is administered within one week before the D96 visit point during the on-demand treatment period, the subject is required to continue follow-up observation for one week after the last dose before completing the end of study visit. PK/PD samples will be collected as appropriate during on-demand treatment, as specified in the schedule for biological sample collection.Observe subject safety throughout the study.

Conditions

Male; Hemophilia A With Inhibitor; Hemophilia B With Inhibitor; Hemophilia

Outcome Measures

Primary Outcomes (4)

• Cmax

  According to the detected FVII activity of SS109 and NovoSeven®, the peak activity (Cmax)

  Day 1 to Day 6

• Four-level rating scale to assess hemostasis

  Hemostasis 12 h after on-demand treatment. For each new blood event, on-demand treatment should be conducted within 15min before each administration after the first dose The hemostatic effect of pain and bleeding symptoms/signs observed and recorded after the last treatment was evaluated according to a four-level scoring scale. If clinically effective (rated as "excellent" or "good") is achieved, the evaluation is discontinued.

  Day 7 to Day 96

• Tmax

  According to the detected FVII activity of SS109 and NovoSeven®,time to peak concentration (Tmax),

  Day 1 to Day 6

• AUC0-t

  area under the concentration-time curve from time 0 to the last quantifiable time point (AUC0-t) will be calculated

  Day 1 to Day 6

Secondary Outcomes (6)

• Efficacy of hemostasis before each dose (except first dose) after treatment of all bleeding events

  Day 7 to Day 96

• Time to "good" or "excellent" evaluation after treatment for all hemorrhage events

  Day 7 to Day 96

• Evaluate the incidence of AE/SAE/AESI

  Day 1 to Day 96

• Incidence of positivity for FVII inhibitors

  Day 1 to Day 96

• anti-drug antibodies (ADAs)

  Day 1 to Day 96

Other Outcomes (6)

• AUC0-inf

  Day 1 to Day 6

• (λz

  Day 1 to Day 6

• t1/2

  Day 1 to Day 6

Study Arms (2)

PK period: Cohort 1 (90 μg/kg) and Cohort 2 (270 μg/kg)

EXPERIMENTAL

In the PK study period, subjects are divided into 2 cohorts (90 μg/kg and 270 μg/kg), which are sequentially conducted. Cohort 1 (90 μg/kg) enrollment is performed firstly, and Cohort 2 (270 μg/kg) enrollment is performed after Cohort 1 enrollment is completed. Subjects enter the PK study period as non-randomized. All screened eligible subjects will receive a single dose of comparator NovoSeven® in the absence of significant active hemorrhage, followed by PK/PD sample collection; then receive a single dose of the same dose of investigational drug SS109, followed by PK/PD sample collection.

Drug: SS109

On-demand treatment period: Group 1：90 μg/kg Group 2：180 μg/kg Group 3：270 μg/kg

EXPERIMENTAL

After completion of the PK study period, subjects will enter a 90-day on-demand treatment period and will be randomized into 3 groups (Group 1: 90 µg/kg, Group 2: 180 µg/kg, and Group 3: 270 µg/kg) at a ratio of 1:1:1. During on-demand treatment, subjects are treated on-demand with SS109 at the time of a new hemorrhage event and their efficacy is observed.

Drug: SS109

Interventions

SS109 DRUG

on-demand treatment with SS109 at the time of a new hemorrhage event

On-demand treatment period: Group 1：90 μg/kg Group 2：180 μg/kg Group 3：270 μg/kg; PK period: Cohort 1 (90 μg/kg) and Cohort 2 (270 μg/kg)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18 to 65 years at the time of informed consent, male;
• Patients with clinical diagnosis of hemophilia A or B (FVIII activity level ≤ 1% or FIX activity level ≤ 2% in the previous or screening period) who meet one of the following conditions:
• FVIII or FIX inhibitor level ≥ 5 Bu/mL at screening; FVIII or FIX inhibitor level \< 5 Bu/mL and ≥ 0.6 Bu/mL at screening, with a high response to coagulation factor VIII or IX for injection (i.e., the patient has a previous history of positive FVIII/FIX inhibitor and inhibitor levels are ≥ 5 Bu/mL after reinfusion of FVIII/FIX).
• No active bleeding symptoms prior to the first dose;
• Subjects or impartial witnesses fully understand and comply with the requirements of the study protocol and are willing to complete the study as planned, and voluntarily cooperate in providing biological samples for testing as required by the protocol;
• Be able to understand the procedures and methods of this clinical trial, and after fully informed consent, the patient voluntarily participates and signs the informed consent form by the patient himself or an impartial witness.

You may not qualify if:

• Patients with a known history of hypersensitivity to the investigational product or any of its components;
• Patients with previous hypersensitivity or anaphylaxis after FVII or IgG2 injection therapy;
• Patients with positive FVII inhibitors or history of positive FVII inhibitors at screening;
• Patients with severe anemia (hemoglobin \< 60 g/L);
• Patients with platelet count \< 100 × 109/L;
• Patients with abnormal liver and kidney function:
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3 times the upper limit of normal (ULN); or
• Serum total bilirubin (TBIL) ≥ 1.5 times ULN; or
• Serum creatinine (Cr) ≥ 1.5 times ULN or creatinine clearance \< 60 mL/min calculated according to the Cockcroft-Gault formula;
• Patients with one or more positive tests for hepatitis B virus surface antigen (HBsAg), anti-hepatitis C virus (HCV) antibody, anti-human immunodeficiency virus (HIV) antibody, and anti-treponema pallidum hemagglutination (TPHA)-specific antibody;
• With the exception of hemophilia A or B, any other haemorrhagic disorders or significantly abnormal coagulation indicators (such as platelet disease, vitamin K deficiency and hypofibrinogenaemia) caused by other diseases;
• Patients with fever, active infection and allergy (such as allergic rhinitis, allergic asthma, allergic dermatitis) within 2 weeks before the first dose;
• Patients with severe cardiovascular and cerebrovascular diseases or thromboembolic diseases occurred within 6 months before the first dose, such as cerebral arteritis, moyamoya disease, cerebral stroke, viral myocarditis, endocarditis, endocardial fibroelastosis, severe arrhythmia, myocardial infarction, unstable angina pectoris, congestive heart failure (New York Heart Association Grade ≥ III), uncontrolled hypertension (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg) and uncontrolled diabetes;
• Patients receiving or planning to receive immune tolerance induction (ITI) treatment during the trial;
• Receipt of any product containing FVII or FVIIa (plasma source or recombinant) within 24 hours before the first dose;

Sponsors & Collaborators

• Jiangsu Gensciences lnc.: lead

Study Sites (9)

Anhui Provincial Hospital

Hefei, China

Location

The First Affiliated Hospital of Shandong First Medical University

Jinan, China

Location

The Second Affiliated Hospital of Kunming Medical University

Kunming, China

Location

Jiangxi Provincial People's Hospital

Nanchang, China

Location

Yangping Song

Shanxi, China

Location

Hematology Hospital, Chinese Academy of Medical Sciences

Tianjin, China

Location

Xi'an Central Hospital

Xi'an, China

Location

Affiliated Hospital of Xuzhou Medical University

Xuzhou, China

Location

Henan Provincial Cancer Hospital

Zhengzhou, China

Location

MeSH Terms

Conditions

Hemophilia A

Condition Hierarchy (Ancestors)

Blood Coagulation Disorders, Inherited; Blood Coagulation Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Coagulation Protein Disorders; Hemorrhagic Disorders; Genetic Diseases, Inborn; Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 15, 2023
• First Posted: August 25, 2023
• Study Start: October 12, 2023
• Primary Completion: May 7, 2024
• Study Completion: May 7, 2024
• Last Updated: July 19, 2024

Record last verified: 2023-11

Locations

CN (9)